Review





Similar Products

cpg odn2395  (InvivoGen)
97
InvivoGen cpg odn2395
Cpg Odn2395, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/pmc13199673-21-0-3?v=InvivoGen
Average 97 stars, based on 1 article reviews
cpg odn2395 - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier
cpg b  (InvivoGen)
97
InvivoGen cpg b
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Cpg B, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/pmc13223964-83-0-2?v=InvivoGen
Average 97 stars, based on 1 article reviews
cpg b - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier
cpgs  (Idera Pharmaceuticals)
86
Idera Pharmaceuticals cpgs
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Cpgs, supplied by Idera Pharmaceuticals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/us12653883-589-13-16?v=Idera+Pharmaceuticals
Average 86 stars, based on 1 article reviews
cpgs - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
cpg odn 1668  (InvivoGen)
97
InvivoGen cpg odn 1668
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Cpg Odn 1668, supplied by InvivoGen, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/us12653800-366-17-23?v=InvivoGen
Average 97 stars, based on 1 article reviews
cpg odn 1668 - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier
class b cpg  (InvivoGen)
98
InvivoGen class b cpg
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Class B Cpg, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/pm42274627-70-0-13?v=InvivoGen
Average 98 stars, based on 1 article reviews
class b cpg - by Bioz Stars, 2026-07
98/100 stars
  Buy from Supplier
electromyography (emg) research  (MyoLearn)
99
MyoLearn electromyography (emg) research
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Electromyography (Emg) Research, supplied by MyoLearn, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/myolearn___emg?v=MyoLearn
Average 99 stars, based on 1 article reviews
electromyography (emg) research - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
alhydrogel adjuvant 2%  (InvivoGen)
98
InvivoGen alhydrogel adjuvant 2%
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Alhydrogel Adjuvant 2%, supplied by InvivoGen, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/invivogen___vaccination?v=InvivoGen
Average 98 stars, based on 1 article reviews
alhydrogel adjuvant 2% - by Bioz Stars, 2026-07
98/100 stars
  Buy from Supplier
dmtr nucleoside succinyl cpg  (Glen Research)
86
Glen Research dmtr nucleoside succinyl cpg
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Dmtr Nucleoside Succinyl Cpg, supplied by Glen Research, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/us12649760-811-12-15?v=Glen+Research
Average 86 stars, based on 1 article reviews
dmtr nucleoside succinyl cpg - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
pb cpg  (Pacific Biosciences)
86
Pacific Biosciences pb cpg
Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg <t>of</t> <t>CpG-B</t> in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.
Pb Cpg, supplied by Pacific Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpg/pm42261605-71-10-13?v=Pacific+Biosciences
Average 86 stars, based on 1 article reviews
pb cpg - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg of CpG-B in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.

Journal: iScience

Article Title: VPS33B regulates MHC class II antigen presentation in dendritic cells to drive CD4 T cell immunity

doi: 10.1016/j.isci.2026.116052

Figure Lengend Snippet: Impaired CD4 and CD8 T cell priming is not due to inherent T cell-intrinsic defects in mice lacking VPS33B in DCs and other myeloid cells (A) Schematic of experimental set-up for adoptive T cell transfer and protein immunization. CD45.1 + OT-I and OT-II T cells were isolated and transferred into VPS33B WT and VPS33B ΔCSF1R mice. 24 h later, mice were immunized with 50 μg of OVA and 5 μg of LPS or 10 μg of CpG-B in IFA (100 μL/mouse; hock injection). 7 days later, IgLNs were collected and subject to flow cytometry. (B) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-II and OT-I cells from immunized LNs to the right. (C) Representative flow plots gating for transferred OT-I (live, CD90.2 + , Vα2 + , CD8 + , CD45.1 + ) or transferred OT-II (live, CD90.2 + , Vα2 + , CD8 − , CD45.1 + ) T cells. Pre-gated on live, CD90.2 + , Vα2 + cells. Quantification of % CD45.1 + , Vα2 + OT-I and OT-II cells from immunized LNs to the right. Error bars shown as mean ± SEM. n = 4–5 biological replicates for one independent experiment. Statistical analysis was performed by unpaired t test. ∗ p < . 05 , ∗∗ p < 0 . 01 , ∗∗∗p < 0 . 0001 , n.s. = not significant.

Article Snippet: CpG-B , Invivogen , Cat#Tlrl-1668.

Techniques: Isolation, Injection, Flow Cytometry